Showing 6 results for Aml
Ghasemi A, Ghotaslou A, Mohammadi M, Ghaffari K, Abbasian S,
Volume 7, Issue 1 (11-2014)
Abstract
Background: In acute myeloblastic leukemia, a large number of tumor suppressor genes are silenced through DNA
methylation such as CDKN2B & p73. Wnt inhibitory factor 1 (WIF1) and Dickkopf-3 (DKK-1) are negative regulators of
Wnt signaling pathway. In the present study, we evaluated the methylation status of WIF1 and DKK-1 genes in acute
myeloblastic leukemia patients.
Patients and Methods: Blood samples were taken from 120 AML patients and 25 healthy control subjects. DNA was
isolated, treated with sodium bisulphite, and examined using methylation-specific polymerase chain reaction (MSP)
with primers specific for methylated and unmethylated sequences of the WIF1 and DKK-1 genes.
Results: The frequency of aberrant hypermethylation of WIF1 and DKK-1 genes in acute myeloblastic leukemia
patients were determined to be 35% (42/120) and 28.3% (34/120), respectively. In addition, for all subjects in control
group, methylation of WIF1 and DKK-1 genes were negative. Patients with M0 subtype of FAB-AML had the highest
incidence of hypermethylation of WIF1 (P = 0.003) and DKK-1 (P = 0.005) genes.
Conclusion: The present study showed that, like many solid tumors, WIF1 and DKK-1 genes methylation also occurs
in acute myeloblastic leukemia. The study of other antagonists of Wnt signaling pathways are recommended.
Key words: AML, Wnt inhibitory factor 1, dickkopf, DNA methylation.
Farhad Shahi, Marziye Ghalamkari, Seyed Reza Safayi, Mehrzad Mirzania, Mahdi Khatuni, Faeze Almasi,
Volume 8, Issue 2 (6-2016)
Abstract
Background: Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) is used as treatment of choice for patients with acute myeloid leukemia (AML). We aimed to evaluate the prognostic factors in 2-year overall survival of patients with non-M3 AML who underwent allogenic HSCT.
Methods: This is a Cross sectional retrospective study. Demographic data and study of variables such as age, sex, complete remission status, Karnofsky performance status scale at baseline and at time of transplantation, occurrence of GVHD (acute and chronic), relapse and 2-year survival were extracted from records of 49 patients who underwent allogenic HSCT from years 2006-2013 at BMT center in Imam Khomeini Hospital. All Autologous SCTs and M3 cases were not included. All data were analyzed with SPSS software. P<0.05 was considered as statistically significant.
Results: The overall survival rate was 55% in the patients. There was no significant difference in overall survival between complete remission (CR) 1 and CR2. Relapse rate was 6%. Mean 2-year Karnofsky scale was 93.7. Mean admission time following BMT was 22 days which was significantly related to 2-year performance status (P=0.02). Admission complication rate was 22.5% (GVHD 12%). Rate of overall GVHD was 55%, 40% of whom developed chronic GVHD which had a positive effect on 2-year overall survival (OS2).The patient’s first performance state (K1) had a significant correlation with 2-year performance state (P<0.05) and OS2 (P<0.05).
Conclusion: Chronic GVHD and initial Karnofsky performance status scale can be considered as good prognostic factors in patients with AML who undergo allo-HSCT.
Afshin Karami, Mehrdad Payandeh, Noorodin Karami, Amir Yami,
Volume 10, Issue 2 (6-2018)
Abstract
Ms Kosar Fateh, Ms Bahareh Kashani, Dr Zahra Hasanpour, Dr Naser Shagerdi Esmaeli, Dr Vahid Amiri, Prof Seyed H. Ghaffari, Dr. Davood Bashash,
Volume 14, Issue 4 (12-2022)
Abstract
Background: Acute myeloid leukemia (AML) is described by the clonal expansion of myeloid blasts with abnormal differentiation. Considering the role of Toll-like receptors (TLRs) in inflammation induction and the effect of chronic inflammation on cancer development, investigating the state of TLRs’ expression in human malignancies has attracted scientists’ attention.
Methods: In this study, 36 newly-diagnosed AML patients and 36 control samples were examined. The mRNA expression levels of TLR1/2/4/7/8 were measured in both groups using real-time PCR. The student’s t-test was utilized to compare gene expression levels between the two populations and the one-way ANOVA test was used to compare data among multiple subtypes.
Results: All TLR gene expression levels were significantly up-regulated in patients compared to the control group (p<0.05). Positive correlations between different TLRs were observed as well. AML patients under the age of 55 showed significantly higher TLR1/2/4 expression in comparison with healthy individuals of the same age; a similar comparison in people above 55 also showed an elevated expression of TLR1/2/4/8. Male patients overexpressed almost all genes compared to healthy subjects; the levels of TLR1/2/4 were also higher in female patients. No difference was observed comparing blast percentages and FAB subtypes.
Conclusion: By considering the results of this experiment, it seems that TLRs up-regulation in AML patients may contribute to the pathogenesis and development of the disease; however, more investigations are required to elucidate the exact roles of these receptors in AML.
./files/site1/files/Supplementary_Fig._1.docx
Dr Hamed Baghdadi, Dr Mehdi Shakouri Khomartash, Nazanin Ahmadi, Dr Ali Faridfar, Dr Mahdi Ghorbani,
Volume 16, Issue 1 (3-2024)
Abstract
| Ikaros zinc finger (IKZF) transcription factors, part of the Krüppel family, have a significant role in the physiological development of immune cells. Ikaros, which is encoded by IKZF1, is a well-researched IKZF transcription factor that specifically impacts the growth and differentiation of lymphocytes. It interacts with various nuclear factors, functioning as either a transcriptional inhibitor or activator; thus, regulates several lymphopoiesis-associated factors like pre-TCR and pre-BCR. Over the years, research has revealed that alterations in IKZF1 as well as Ikaros can cause out-of-control differentiation and proliferation of immune cells, particularly lymphocytes, potentially triggering tumorigenesis in hematologic malignancies such as ALL, AML, CLL, and CML. Recent studies have explored the therapeutic potential of targeting Ikaros or restoring its activities to limit the pathologic differentiation and proliferation of tumor cells. Most of these therapeutic agents are immunomodulatory drugs (IMiDs) that can selectively ubiquitinate and proteasome degrade Ikaros. This study offers a comprehensive overview of Ikaros’s physiological roles and highlights the oncogenic characteristics of IKZF1 and Ikaros alterations. |
Mr Mohammadreza Moonesi, Mrs Hanie Mehdizade, Mr Saeed Zakakhosravi, Mrs Samira Molaei Ramshe, Dr Mehdi Allahbakhshian, Dr Saeed Solali, Dr Majid Farshdousti Hagh,
Volume 16, Issue 3 (9-2024)
Abstract
Background: One of the most common types of leukemia is acute myeloid leukemia (AML). Intrinsic and extrinsic factors may lead to AML. Insulin-like growth factor (IGF) is a mitogenic intermediate from the liver that regulates growth and proliferation in response to GH. In this study, we examined the expression of IGF family genes in bone marrow of AML patients (M3 and Non-M3) and compared them with normal samples.
Methods: Forty bone marrow samples from recently diagnosed AML patients along with 15 samples from subjects without hematological malignancies were collected. For molecular tests, RNA extraction and cDNA synthesis were performed. Finally, IGF1, IGF2, IGFBP3, IGF1R, and IGF2R gene expression were examined by Real-Time PCR.
Results: IGF1, IGF1R, and IGFBP3 gene expression were significantly increased in patients with AML. In contrast, IGF2 and IGF2R genes did not show significant expression changes between the two groups.
Conclusion: The expression in this gene family soared in AML patients' bone marrow, compared to normal subjects. This can be caused by malignant cells in the bone marrow. These malignant cells express proteins that increase the number of malignant cells. Moreover, they can be considered as diagnostic biomarkers or therapeutic targets with further research.
